Try GOLD - Free
US generics, domestic market to drive pharma cos' Q4 sales growth
Mint New Delhi
|April 29, 2025
Analysts anticipate higher sales of Revlimid to drive growth for US-focused firms such as Sun Pharma in Q4
Pharma companies are expected to report healthy revenue growth of 11-13% in the fourth quarter of FY25, driven by strong traction in niche US generic drugs, steady domestic performance in a seasonally weak quarter and higher sales of a blockbuster cancer drug in the US before its distribution exclusivity ends next year, analysts said.
Uncertainties over US tariffs and the end of the limited competition period for generic Revlimid in the US loom in the months ahead. However, analysts anticipate higher sales of Revlimid to drive growth for US-focused companies such as Aurobindo Pharma Ltd, Dr Reddy's Laboratories Ltd and Sun Pharmaceutical Industries Ltd in Q4 and the first few quarters of the next fiscal.
This story is from the April 29, 2025 edition of Mint New Delhi.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Mint New Delhi
Mint New Delhi
Tech solutions exist to mitigate KYC data leakage risks
Today, more than half of all data breach incidents target personally identifiable information—tax identities, passport numbers, biometric data and the like.
3 mins
January 07, 2026
Mint New Delhi
Maduro’s capture threatens China's ambitions in Latin America
Beijing has steadily built relationships over the past two decades in Washington's backyard
4 mins
January 07, 2026
Mint New Delhi
Wall Street investors who stuck with Venezuela are poised for a payday
The ouster of Nicolas Maduro is rewarding investors who spent years betting on a Venezuela comeback.
4 mins
January 07, 2026
Mint New Delhi
TVs ward off smartphone threat with AI
Uber robotaxis are on their way in, in 2026—and other AI news this week
1 min
January 07, 2026
Mint New Delhi
Much can be done to relieve urban India of its toxic air
Air pollution in the National Capital Region (NCR) continues to dominate headlines this winter, highlighting the absence of any long-term strategy to deal with a deadly subject that is affecting millions of lives in and around India’s capital.
3 mins
January 07, 2026
Mint New Delhi
Modulus taps UBS for private credit biz
Modulus Alternatives Investment Managers hired a veteran banker from UBS Group AG to lead its private credit business, according to people familiar with the matter, as demand for talent in the sector heats up.
1 min
January 07, 2026
Mint New Delhi
NHAI asks DoT to fix mobile network gaps on highways
As India builds highways at a record pace, a critical digital gap is becoming harder to ignore.
1 min
January 07, 2026
Mint New Delhi
Hospitals are a proving ground for what AI can do, and what it can't
Amir Abboud, chief of emergency radiology for Northwestern Medicine, thought he was already working at maximum speed.
6 mins
January 07, 2026
Mint New Delhi
Mid-sized startups ditch unicorn chase, pursue IPOs earlier
According to one of the people cited above, these startups are likely to raise ₹400-600 crore through IPOs.
2 mins
January 07, 2026
Mint New Delhi
Gold price spike lifts Titan Q3 sales
Titan Company on Tuesday posted a 40% jump in overall sales for the December quarter, driven by a higher average selling price for its gold jewellery and festive demand.
1 min
January 07, 2026
Listen
Translate
Change font size